Clinical trial
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous…
NCT00500006 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00500006 |
|---|---|
| Title | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) |
| Official title | A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
| Intervention type | Drug |
| Interventions | MK0457, dasatinib |
| Enrollment | 3 |
| Start date | Oct 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jul 12, 2007 |
| Last update posted | Jan 30, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: